孟鲁司特钠联合布地奈德福莫特罗治疗咳嗽变异性哮喘的疗效观察

Effect of Montelukast Sodium Combined with Budesonide Formoterol in the Treatment of Cough Variant Asthma

目的:观察孟鲁司特钠联合布地奈德福莫特罗治疗咳嗽变异性哮喘(CVA)的临床疗效。方法:90例CVA患者按照随机数字表法分为对照组与研究组,各45例,两组入院后均予以常规措施治疗,对照组在常规治疗基础上加用布地奈德福莫特罗吸入剂治疗,观察组在对照组基础上加用孟鲁司特钠片治疗,两组均连续治疗8周。比较两组治疗前后咳嗽评分、炎症细胞因子及肺功能指标。结果:治疗前,两组日间及夜间咳嗽评分,肿瘤坏死因子-α(tumor necrosis factor,TNF-α)、白细胞介素-5(interleukin-5,IL-5)、白细胞介素-6(interleukin-6,IL-6)比较,差异均无统计学意义(P>0.05)。治疗后,两组日间及夜间咳嗽评分,TNF-α、IL-5及IL-6均明显低于治疗前(P<0.05),且观察组治疗后日间及夜间咳嗽评分,TNF-α、IL-5及IL-6均明显低于对照组(P<0.05)。治疗前,两组1秒用力呼吸量(forced expiratory volume in one second,FEV1)、肺活量(fast vital capacity,FVC)、最大呼气峰流速(peak expiratory flow,PEF)比较,差异均无统计学意义(P>0.05)。治疗后,两组FEV1、FVC、PEF均明显高于治疗前(P<0.05),且观察组治疗后FEV1、FVC、PEF均明显高于对照组(P<0.05)。结论:孟鲁司特钠联合布地奈德福莫特罗治疗可明显缓解CVA患者咳嗽症状,减轻炎症反应和改善肺功能。

Objective:To observe the clinical effect of Montelukast Sodium combined with Budesonide Formoterol in the treatment of cough variant asthma(CVA).Method:90 cases of CVA patients were divided into control group and observation group according to the random number table method,45 cases in each group.Both groups were treated with routine measures after admission.The control group was treated with Budesonide Formoterol inhalation on the basis of the routine treatment,and the observation group was treated with Montelukast Sodium Tablets on the basis of the control group.The cough score,the inflammatory cytokines and the pulmonary function indexes of the two groups before and after treatment were compared.Result:Before treatment,there was no significant difference about the daytime and nighttime cough scores,tumor necrosis factor-α(TNF-α),interleukin-5(IL-5),interleukin-6(IL-6)between the two groups(P>0.05).After treatment,the daytime and nighttime cough scores and TNF-α,IL-5 and IL-6 of the two groups were significantly lower than those before treatment(P<0.05),the daytime and nighttime cough scores and TNF-α,IL-5 and IL-6 of the observation group were significantly lower than those of the control group(P<0.05).Before treatment,there was no significant difference about the forced expiratory volume in one second(FEV1),fast vital capacity(FVC),peak expiratory flow(PEF)between the two groups(P>0.05),After treatment,FEV1,FVC and PEF of the two groups were significantly higher than those before treatment(P<0.05);FEV1,FVC and PEF of the observation group were significantly higher than those of the control group(P<0.05).Conclusion:The treatment of Montelukast Sodium combined with Budesonide Formoterol for the patients with CVA can significantly relieve cough symptoms,reduce inflammation and improve lung function.